Caprolactam Chem (507486)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹52.41, this is a ₹25 crore micro-cap in commodity chemicals. Benjamin Graham would tell me to ignore the 69.58 trailing P/E because earnings are minuscule – the latest quarter net profit is ₹0 crore, so trailing profit is not a sign of health. The 1000% profit growth looks exciting, but that is from a hopelessly low base. ROCE at -0.48% tells me the company does not even earn its cost of capital. ROE of 8.89% is below what I would want from a business with so little moat. Commodity chemicals are price-takers; without pricing power, a company is at the mercy of the cycle. On the positive side, sales grew 11.79% and the Piotroski F-Score is 6/9, suggesting some operational discipline. The PEG ratio of 0.14 is a statistical illusion created by distorted profit growth; I cannot rely on it. Book value is ₹12.18, so the P/B of 4.30 is not cheap. There is no dividend to compensate me while I wait. This looks like a cyclical recovery candidate, not a predictable compounder. I need to see several quarters of real profits and positive ROCE before I consider a margin of safety. At this price, with zero current earnings and negative return on capital, the risk is too high for my temperament.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer